Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE (palbociclib) and talazoparib in Combination with CB-839
SAGA Metals Reports More Significant Assays Including 109.1 m at 49.88% Fe2O3, 8.53% TiO2, 0.316% V2O5 at the Radar Critical Minerals Project
SAGA Metals Reports More Significant Assays Including 109.1 m at 49.88% Fe2O3, 8.53% TiO2, 0.316% V2O5 at the Radar Critical Minerals Project
Metalsource Mining Receives $1.38 Million from Eric Sprott Warrant Exercise as Silver Hill Gold-Silver Exploration Advances